Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule
Galmed Pharmaceuticals (NASDAQ: GLMD) said Nasdaq granted an additional 180 days, extending the deadline to Jan. 25, 2027, to regain compliance with the $1 minimum bid price rule. Nasdaq initially notified GLMD on Jan. 29, 2026, and the prior deadline was July 28, 2026. Compliance requires a $1 or higher close for 10 straight trading days.
How this was made
The 30-second read
Why it matters
The new 180-day extension delays potential delisting actions and provides a defined compliance path: a $1-or-higher close for at least 10 consecutive trading days before Jan 25, 2027.
Market read
This is a listing-risk timeline update that can affect short-term trading and risk management for GLMD, but it is not a fundamental earnings or clinical catalyst.
What to watch
Traders should focus on the probability of achieving 10 consecutive closes above $1 before Jan 25, 2027, which depends on liquidity, reverse-split risk, and ongoing trading behavior.
Background
Nasdaq notified Galmed in Jan 2026 that its shares traded below $1 for 30 consecutive days, and the company missed the initial July 28, 2026 deadline.
Ticker impact
Nasdaq granted Galmed an additional 180 days, until Jan 25, 2027, to regain compliance with the $1 minimum bid rule.
Likely modest relief bid, with continued volatility tied to whether GLMD can close above $1 for 10 consecutive sessions before the new deadline.
The article is a regulatory listing-compliance update, not an operating or financial catalyst. It changes the timeline for delisting risk, which can affect sentiment and liquidity, but does not guarantee compliance.
Market effects
Microcap biotech listing-compliance stories can influence risk premia for similar Nasdaq $1-bid names, but this is company-specific.
Primarily affects US small-cap sentiment and Nasdaq listing-risk screening.
Limited, as the catalyst is a Nasdaq rule compliance timeline for a single issuer.
Counterpoint
The extension may not change fundamentals, so any relief rally could fade if GLMD remains structurally below $1.
Key entities
- companyGalmed Pharmaceuticals Ltd.
Nasdaq-listed issuer seeking compliance with the $1 minimum bid price requirement.
- regulationNasdaq Listing Rule 5550(a)(2)
Minimum $1 bid price requirement that triggers compliance and potential delisting processes.
